On the other hand, our clinical findings in HCC and PDAC at least suggest that the upregulation of NG2/CSPG4 is associated with poor prognoses in these solid organ cancers and could be useful as an additional prognostic marker to increase the resolution of traditional approaches. Here, CSPG4 is linked to hepatocellular carcinoma.